Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Next, the company says they have a pill coming that could ... high-demand drugs now known as "weight-loss" shots: Mounjaro, prescribed for diabetes, and Zepbound, for obesity.

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs ... “He thinks it’s as easy as taking a pill.” “And I got so angry,” Jeanne ...

While Zepbound is FDA-approved for weight loss, Mounjaro is approved for managing ... but it is taken as an oral pill rather than an injection. Who is it for? Rybelsus is approved for adults ...

Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Eli Lilly and Novo Nordisk, which dominate the market with their obesity injections Zepbound and Wegovy, respectively, are both looking to develop next-generation versions. A weight loss pill ...